These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

424 related items for PubMed ID: 15126001

  • 1. Prostaglandin E1 in lipid microspheres ameliorates diabetic peripheral neuropathy: clinical usefulness of Semmes-Weinstein monofilaments for evaluating diabetic sensory abnormality.
    Akahori H, Takamura T, Hayakawa T, Ando H, Yamashita H, Kobayashi K.
    Diabetes Res Clin Pract; 2004 Jun; 64(3):153-9. PubMed ID: 15126001
    [Abstract] [Full Text] [Related]

  • 2. Prostaglandin E1 incorporated in lipid microspheres in the treatment of peripheral vascular diseases and diabetic neuropathy.
    Hoshi K, Mizushima Y, Kiyokawa S, Yanagawa A.
    Drugs Exp Clin Res; 1986 Jun; 12(8):681-5. PubMed ID: 3757764
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Effectiveness of Semmes-Weinstein monofilament examination for diabetic peripheral neuropathy screening.
    Kamei N, Yamane K, Nakanishi S, Yamashita Y, Tamura T, Ohshita K, Watanabe H, Fujikawa R, Okubo M, Kohno N.
    J Diabetes Complications; 2005 Jun; 19(1):47-53. PubMed ID: 15642490
    [Abstract] [Full Text] [Related]

  • 6. PGE1 improves diabetic peripheral neuropathy in patients with type 2 diabetes.
    Wu JD, Tao S, Jin X, Jiang LL, Shen Y, Luo Y, Zhang P, Lee KO, Ye L, Ma JH.
    Prostaglandins Other Lipid Mediat; 2016 Nov; 126():24-28. PubMed ID: 27421690
    [Abstract] [Full Text] [Related]

  • 7. A multicenter double blind controlled study of lipo-PGE1, PGE1 incorporated in lipid microspheres, in peripheral vascular disease secondary to connective tissue disorders.
    Mizushima Y, Shiokawa Y, Homma M, Kashiwazaki S, Ichikawa Y, Hashimoto H, Sakuma A.
    J Rheumatol; 1987 Feb; 14(1):97-101. PubMed ID: 3553591
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Effects of a single drip infusion of lipo-prostaglandin E1 on vibratory threshold in patients with diabetic neuropathy.
    Tawata M, Nitta K, Kurihara A, Nagasaka T, Iwase E, Gan N, Inoue M, Onaya T.
    Prostaglandins; 1995 Jan; 49(1):27-39. PubMed ID: 7792389
    [Abstract] [Full Text] [Related]

  • 10. Treatment of established collagen induced arthritis with prostaglandin E1 incorporated in lipid microspheres.
    Moriuchi-Murakami E, Yamada H, Ishii O, Kikukawa T, Igarashi R.
    J Rheumatol; 2000 Oct; 27(10):2389-96. PubMed ID: 11036835
    [Abstract] [Full Text] [Related]

  • 11. Lipo-prostaglandin E1 in combination with steroid therapy is effective for treatment of sudden sensorineural hearing loss in Korean patients with Type 2 diabetes.
    Ahn JH, Kim TY, Kim YJ, Han MW, Yoon TH, Chung JW.
    Diabet Med; 2006 Dec; 23(12):1339-43. PubMed ID: 17116185
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Clinical usefulness of the two-site Semmes-Weinstein monofilament test for detecting diabetic peripheral neuropathy.
    Lee S, Kim H, Choi S, Park Y, Kim Y, Cho B.
    J Korean Med Sci; 2003 Feb; 18(1):103-7. PubMed ID: 12589096
    [Abstract] [Full Text] [Related]

  • 14. Does anodyne light therapy improve peripheral neuropathy in diabetes? A double-blind, sham-controlled, randomized trial to evaluate monochromatic infrared photoenergy.
    Lavery LA, Murdoch DP, Williams J, Lavery DC.
    Diabetes Care; 2008 Feb; 31(2):316-21. PubMed ID: 17977931
    [Abstract] [Full Text] [Related]

  • 15. Use of the C64 quantitative tuning fork and the effect of niceritrol in diabetic neuropathy.
    Hotta N, Sugimura K, Tsuchida I, Sano T, Koh N, Matsumae H, Sakamoto N.
    Clin Ther; 1994 Feb; 16(6):1007-15. PubMed ID: 7697680
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Prostaglandin E1 incorporated in lipid microspheres (lipo PGE1).
    Otomo S, Mizushima Y, Aihara H, Yokoyama K, Watanabe M, Yanagawa A.
    Drugs Exp Clin Res; 1985 Feb; 11(9):627-31. PubMed ID: 3880049
    [Abstract] [Full Text] [Related]

  • 18. A comparison of the effect of Lipo PGE1 and other related compounds on experimental peripheral arterial occlusive disease in rats.
    Goto J, Araki H, Otomo S, Aihara H.
    Drugs Exp Clin Res; 1986 Feb; 12(11):917-21. PubMed ID: 3816509
    [Abstract] [Full Text] [Related]

  • 19. C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy.
    Ekberg K, Brismar T, Johansson BL, Lindström P, Juntti-Berggren L, Norrby A, Berne C, Arnqvist HJ, Bolinder J, Wahren J.
    Diabetes Care; 2007 Jan; 30(1):71-6. PubMed ID: 17192336
    [Abstract] [Full Text] [Related]

  • 20. Development and validity testing of the neuropathy total symptom score-6: questionnaire for the study of sensory symptoms of diabetic peripheral neuropathy.
    Bastyr EJ, Price KL, Bril V, MBBQ Study Group.
    Clin Ther; 2005 Aug; 27(8):1278-94. PubMed ID: 16199253
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.